↓ Skip to main content

Phosphodiesterases: CNS Functions and Diseases

Overview of attention for book
Cover of 'Phosphodiesterases: CNS Functions and Diseases'

Table of Contents

  1. Altmetric Badge
    Book Overview
  2. Altmetric Badge
    Chapter 1 Phosphodiesterase Diversity and Signal Processing Within cAMP Signaling Networks
  3. Altmetric Badge
    Chapter 2 Current Understanding of PDE10A in the Modulation of Basal Ganglia Circuitry
  4. Altmetric Badge
    Chapter 3 Interaction of Cdk5 and cAMP/PKA Signaling in the Mediation of Neuropsychiatric and Neurodegenerative Diseases
  5. Altmetric Badge
    Chapter 4 The PDE4 cAMP-Specific Phosphodiesterases: Targets for Drugs with Antidepressant and Memory-Enhancing Action
  6. Altmetric Badge
    Chapter 5 Phosphodiesterase-4B as a Therapeutic Target for Cognitive Impairment and Obesity-Related Metabolic Diseases
  7. Altmetric Badge
    Chapter 6 From Age-Related Cognitive Decline to Alzheimer’s Disease: A Translational Overview of the Potential Role for Phosphodiesterases
  8. Altmetric Badge
    Chapter 7 The Past, Present, and Future of Phosphodiesterase-4 Modulation for Age-Induced Memory Loss
  9. Altmetric Badge
    Chapter 8 A Role for Phosphodiesterase 11A (PDE11A) in the Formation of Social Memories and the Stabilization of Mood
  10. Altmetric Badge
    Chapter 9 Role of PDE9 in Cognition
  11. Altmetric Badge
    Chapter 10 Regulation of Striatal Neuron Activity by Cyclic Nucleotide Signaling and Phosphodiesterase Inhibition: Implications for the Treatment of Parkinson’s Disease
  12. Altmetric Badge
    Chapter 11 Role of Phosphodiesterases in Huntington’s Disease
  13. Altmetric Badge
    Chapter 12 The Role of Phosphodiesterase-2 in Psychiatric and Neurodegenerative Disorders
  14. Altmetric Badge
    Chapter 13 Phosphodiesterase 1: A Unique Drug Target for Degenerative Diseases and Cognitive Dysfunction
  15. Altmetric Badge
    Chapter 14 PDE Inhibitors for the Treatment of Schizophrenia
  16. Altmetric Badge
    Chapter 15 Targeting Phosphodiesterases in Pharmacotherapy for Substance Dependence
  17. Altmetric Badge
    Chapter 16 Genetic Understanding of Stroke Treatment: Potential Role for Phosphodiesterase Inhibitors
  18. Altmetric Badge
    Chapter 17 A Unique Sub-Pocket for Improvement of Selectivity of Phosphodiesterase Inhibitors in CNS
Attention for Chapter 6: From Age-Related Cognitive Decline to Alzheimer’s Disease: A Translational Overview of the Potential Role for Phosphodiesterases
Altmetric Badge

Readers on

mendeley
41 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Chapter title
From Age-Related Cognitive Decline to Alzheimer’s Disease: A Translational Overview of the Potential Role for Phosphodiesterases
Chapter number 6
Book title
Phosphodiesterases: CNS Functions and Diseases
Published in
Advances in neurobiology, January 2017
DOI 10.1007/978-3-319-58811-7_6
Pubmed ID
Book ISBNs
978-3-31-958809-4, 978-3-31-958811-7
Authors

Pim R. A. Heckman, Arjan Blokland, Jos Prickaerts

Abstract

Phosphodiesterase inhibitors (PDE-Is) are pharmacological compounds enhancing cAMP and/or cGMP signaling. Both these substrates affect neural communication by influencing presynaptic neurotransmitter release and postsynaptic intracellular pathways after neurotransmitter binding to its receptor. Both cAMP and cGMP play an important role in a variety of cellular functions including neuroplasticity and neuroprotection. This chapter provides a translational overview of the effects of different classes of PDE-Is on cognition enhancement in age-related cognitive decline and Alzheimer's disease (AD). The most effective PDE-Is in preclinical models of aging and AD appear to be PDE2-Is, PDE4-Is and PDE5-Is. Clinical studies are relatively sparse and so far PDE1-Is and PDE4-Is showed some promising results. In the future, the demonstration of clinical proof of concept and the generation of isoform selective PDE-Is are the hurdles to overcome in developing safe and efficacious novel PDE-Is for the treatment of age-related cognitive decline and cognitive dysfunction in AD.

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 41 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 41 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 10 24%
Student > Master 7 17%
Researcher 5 12%
Student > Ph. D. Student 5 12%
Other 1 2%
Other 3 7%
Unknown 10 24%
Readers by discipline Count As %
Neuroscience 8 20%
Pharmacology, Toxicology and Pharmaceutical Science 4 10%
Biochemistry, Genetics and Molecular Biology 4 10%
Psychology 4 10%
Medicine and Dentistry 2 5%
Other 5 12%
Unknown 14 34%